Clotisprin

Clotisprin

Manufacturer:

Pell Tech Healthcare

Distributor:

Macropharma Corp

Marketer:

Ambica
Concise Prescribing Info
Contents
Clopidogrel bisulfate 75 mg, aspirin 75 mg
Indications/Uses
Reduction of thrombotic events in patients w/ recent MI, recent stroke or established peripheral arterial disease. Acute coronary syndrome.
Dosage/Direction for Use
Prevention of ischemic events 1 cap once daily. Acute coronary syndrome Maintenance: 1 cap daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to clopidogrel, aspirin &/or NSAIDs. Recent history of GI bleeding. Active pathological bleeding eg, peptic ulcer or intracranial hemorrhage, or bleeding disorders like hemophilia.
Special Precautions
Patients who have lesions w/ a propensity to bleed (eg, ulcers). Reye's syndrome may develop in patients w/ chicken pox, flu or flu symptoms. Patients w/ nasal polyps or nasal allergies. Hepatic & renal impairment. Pregnancy (3rd trimester) & lactation. Childn. Clopidogrel: Thrombotic thrombocytopenic purpura. Concomitant use w/ other NSAIDs. Increased risk of bleeding from trauma, surgery, or other pathological conditions. Discontinue 7 days prior to surgery. Aspirin: Hypersensitivity to anti-inflammatory or antirheumatic drugs & other allergens. History of GI disorders. Salicylate intoxication (salicylism) in large doses &/or prolonged therapy.
Adverse Reactions
Abdominal pain, dyspepsia, gastritis, diarrhea, nausea, vomiting, constipation, GI hemorrhage, ulceration, neutropenia, rash, palpitation, syncope, drowsiness, asthenia, neuralgia, paresthesia & vertigo.
Drug Interactions
May increase bleeding time of anticoagulants. Increased risk of GI ulceration w/ pyrazolone derivatives (phenylbutazone, oxyphenylbutazone & dipyrone). Clopidogrel: Increased occult GI blood loss w/ naproxen. May interfere w/ the metabolism of phenytoin, tamoxifen, tolbutamide, torsenamide & fluvastatin. Aspirin: May enhance effect of oral hypoglycemic. May decrease uricosuric effects of probenecid, sulfinpyrazone & phenylbutazone. May decrease Na excretion produced by spironolactone. Produce changes in thyroid function test. Increased risk of GI bleeding. Increased risk of GI ulceration & reduce serum salicylate level w/ corticosteroids. Decreased effectiveness w/ urinary alkalinizers & phenobarb. May increase levels of phenytoin.
ATC Classification
B01AC30 - combinations ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Presentation/Packing
Form
Clotisprin cap
Packing/Price
100's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in